Flag of the European Union EU Clinical Trials Register Help

Clinical trials for vaccines

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    914 result(s) found for: vaccines. Displaying page 12 of 46.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    EudraCT Number: 2021-001040-10 Sponsor Protocol Number: CoVVac Start Date*: 2021-04-26
    Sponsor Name:Medical University of Graz
    Full Title: Humoral and cellular immune response to COVID-19 vaccines in immunocompromised and healthy individuals – The CoVVac study
    Medical condition: Active immunisation to prevent COVID-19 in immunocompromised individuals.
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023313-57 Sponsor Protocol Number: INF Start Date*: 2012-04-10
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Homing potential of the antigen specific B cell and antibody mediated immune response after vaccination
    Medical condition: Basic healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002081-39 Sponsor Protocol Number: V58P16 Start Date*: 2013-10-08
    Sponsor Name:Novartis Vaccines & Diagnostics AG
    Full Title: A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to < 48 Months of Age.
    Medical condition: healthy volunteers (protection against influenza)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004865 10016794 Flu vaccination LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-004304-19 Sponsor Protocol Number: 117119 Start Date*: 2015-07-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa™ vaccine when administered to healthy infants as primary v...
    Medical condition: Active immunization against diphtheria, tetanus, pertussis infection caused by all known subtypes of hepatitis B virus, poliomyelitis, and invasive disease caused by Haemophilus influenzae type B (...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002978-36 Sponsor Protocol Number: OVG2014/08 Start Date*: 2015-01-26
    Sponsor Name:The University of Oxford
    Full Title: Vaccines Against Salmonella Typhi: a phase IIb, single centre, observer-blind, randomised controlled trial to assess the immunogenicity and protective efficacy of Vi conjugated (Vi-TCV) and unconju...
    Medical condition: Salmonella enterica serovar Typhi infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10039446 Salmonella typhi infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-004194-27 Sponsor Protocol Number: 112957 Start Date*: 2015-06-24
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, randomized, multicenter study, double-blind for the immunogenicity and consistency evaluation of 3 lots of GSK Biologicals’ Haemophilus influenzae type b (Hib) conjugate vaccine and si...
    Medical condition: Active immunization against Haemophilus influenzae type b starting from 6 weeks of age as a 3-dose primary series with a single booster dose given at 15 to 18 months
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-005273-31 Sponsor Protocol Number: HPARSRSG12/06 Start Date*: 2013-05-30
    Sponsor Name:Public Health England
    Full Title: A phase III/IV randomised open-label study and comparison of the immunogenicity and safety of a single adolescent booster dose of a meningococcal group C conjugate-containing booster vaccine (Menin...
    Medical condition: Prevention of meningitis C and pertussis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10006021 Booster LLT
    14.1 10021881 - Infections and infestations 10028910 Neisseria meningitides meningitis LLT
    14.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    14.1 10042613 - Surgical and medical procedures 10069593 Pertussis immunization LLT
    14.1 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    16.0 10021881 - Infections and infestations 10027275 Meningococcal infection, unspecified LLT
    14.1 10021881 - Infections and infestations 10034738 Pertussis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003953-43 Sponsor Protocol Number: VAC31518COV3005 Start Date*: 2021-11-29
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older
    Medical condition: Healthy Volunteers (Prevention of COVID-19 and influenza)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    21.1 100000004865 10059430 Influenza immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000145-39 Sponsor Protocol Number: V59_66 Start Date*: 2013-07-31
    Sponsor Name:Novartis Vaccines and Diagnostics s.r.l
    Full Title: A Phase 3, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine, administered to Health...
    Medical condition: To demonstrate non-inferiority of MenACWY vaccine to that of MenC vaccine given to healthy toddlers, as measured by the percentage of subjects with serum bactericidal assay using human complement...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Temporarily Halted) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000476-34 Sponsor Protocol Number: V59_40 Start Date*: 2011-06-08
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase IV,PlaceboControlled,Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix) and Quadrivale...
    Medical condition: Menveo is indicated for active immunization of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    14.1 10021881 - Infections and infestations 10027276 Meningococcal meningitis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004380-44 Sponsor Protocol Number: 112899 Start Date*: 2015-05-20
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase II, open-label, randomised controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis (TB) vaccine (M72/AS01E) when administered i...
    Medical condition: Healthy volunteers (evaluation of safety and reactogenicity of TB vaccine when administered in healthy infants)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-000862-13 Sponsor Protocol Number: V59_67 Start Date*: 2013-07-18
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals...
    Medical condition: To assess the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10027202 Meningitis bacterial PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002537-37 Sponsor Protocol Number: 114858 Start Date*: 2015-07-23
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biologicals' meningococcal conjugate vaccine, MenACWY-TT (GSK 134612) in healthy ...
    Medical condition: Active immunisation of healthy infants to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002919-33 Sponsor Protocol Number: 207911 Start Date*: 2018-03-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Phase IV, open-label, randomized study to enrol healthy adult volunteers, naïve to any previous meningococcal vaccination or meningococcal disease, aged 18-50 years, to be either vaccinated with GS...
    Medical condition: Meningitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001619-31 Sponsor Protocol Number: ONY-P1-06-01 Start Date*: 2006-07-14
    Sponsor Name:Onyvax Limited
    Full Title: A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT
    Medical condition: Prostate cancer without detectable metastases following initial escape from hormone treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) EE (Prematurely Ended) LT (Prematurely Ended) LV (Completed) HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005154-57 Sponsor Protocol Number: CACZ885D2307E1 Start Date*: 2012-01-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndrom...
    Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10068850 Cryopyrin associated periodic syndrome PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) ES (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005427-20 Sponsor Protocol Number: C4601003 Start Date*: 2022-07-13
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6 VALENT OspA-BASED LYME DISE...
    Medical condition: Prevention of Lyme disease caused by Borrelia species in individuals ≥5 years of age by active immunization
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10025169 Lyme disease PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) EE (Prematurely Ended) FI (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005743-27 Sponsor Protocol Number: 116485,SPNG-009 Start Date*: 2012-05-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, controlled, partially-blind study to demonstrate immunogenicity and assess safety of GlaxoSmithKline (GSK) Biologicals’ pneumococcal vaccines (2830929A and 2830930A) adminis...
    Medical condition: 3-dose primary vaccination against Streptococcus pneumoniae and Haemophilus influenzae in healthy infants between 6-12 weeks of age at the time of the first vaccination and booster vaccination at 1...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10042196 Streptococcus pneumoniae secondary bacterial infection of acute bronchitis LLT
    14.1 100000004862 10042197 Streptococcus pneumoniae septicaemia LLT
    14.1 100000004862 10042195 Streptococcus pneumoniae pneumonia LLT
    14.1 100000004862 10042194 Streptococcus pneumoniae meningitis LLT
    14.1 100000004862 10018954 Haemophilus influenzae secondary bacterial infection of acute bronchitis LLT
    14.1 100000004862 10054642 Streptococcus pneumoniae septicemia LLT
    14.1 100000004862 10018953 Haemophilus influenzae meningitis LLT
    14.1 100000004862 10018952 Haemophilus influenzae infection LLT
    14.1 100000004862 10058214 Septicaemia due to haemophilus influenzae (H. influenzae) LLT
    14.1 100000004862 10035680 Pneumonia due to Haemophilus influenzae (H. influenzae) LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001666-15 Sponsor Protocol Number: 205416 Start Date*: 2020-08-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to hea...
    Medical condition: Healthy volunteers (Active immunization against invasive disease caused by N. meningitidis serogroups A, B, C, W and Y)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) EE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-001534-13 Sponsor Protocol Number: V58P12 Start Date*: 2007-11-08
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cel...
    Medical condition: Healthy pediatric population from 3-17 years
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 8  9  10  11  12  13  14  15  16  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Sep 13 21:16:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA